From the aCenter for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, and bDepartment of Medicine, Indiana University School of Medicine and the Richard L. Roudebush VA Medical Center, Indianapolis, Indiana.
J Natl Compr Canc Netw. 2014 Apr;12(4):502-11. doi: 10.6004/jnccn.2014.0055.
As patients with multiple myeloma live longer, helping them live better through improvements in supportive care is equally as vital. Intrinsic to the disease are bone-related complications at presentation and over the course of illness. Bisphosphonates have been an important therapy for ameliorating the risk of skeletal-related events, and work is ongoing to determine their optimal schedule. Patients with multiple myeloma also encounter several challenges related to their treatment, including peripheral neuropathy, thrombotic complications, and infections. These challenges are being addressed through a better understanding of the risk factors for developing these complications and by mitigating these risks through better dosing schemas and prophylaxis.
随着多发性骨髓瘤患者的寿命延长，通过改善支持性护理来帮助他们更好地生活同样至关重要。该疾病从一开始就存在与骨骼相关的并发症，并且在整个病程中都会出现。双膦酸盐类药物一直是改善骨骼相关事件风险的重要治疗方法，目前正在努力确定其最佳方案。多发性骨髓瘤患者在治疗过程中还会遇到一些挑战，包括周围神经病变、血栓并发症和感染。通过更好地了解发生这些并发症的风险因素，并通过更好的剂量方案和预防措施来降低这些风险，正在解决这些挑战。
